Subscribe To
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
  
  Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued strong demand with growth week-over-week starting in August; permanent J-code effective as of October 1 Completed corporate restructuring aimed at driving growth of SYFOVRE and EMPAVELI and strengthening operational […] The post Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results a...  
  Read More  
  
   Posted: Nov 1 2023, 11:05
   Author Name: forextv
   Views: 110488